Ermium Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Ermium Therapeutics was a Paris-based biotechnology company developing innovative therapies for auto-immune diseases. Founded in 2019, it discovered and developed orally available small molecules targeting type I interferon-mediated diseases — systemic lupus erythematosus (SLE), dermatomyositis, Sjogren syndrome, and monogenic interferonopathies — with first-in-class compounds acting on the CXCR4 chemokine receptor via a novel mechanism of action.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Liquidation
Ermium entered judicial liquidation in July 2024 after a safeguard procedure opened earlier that year.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.